Purple Biotech Ltd. is a clinical stage biotechnology company focused on developing next generation immunotherapy for oncology. The company is headquartered in Rehovot Israel and its pipeline includes the CAPTN three specific antibody platform the CEACAM1 blocking antibody CM24 and the dual IRS1 2 and STAT3 inhibitor NT219.

Purple Biotech Ltd. has not yet commercialized any therapeutic product and therefore does not generate product revenue. The company’s current activities are financed through research collaborations licensing discussions and capital raising efforts to advance its pipeline candidates.

Within the competitive oncology therapeutics landscape Purple Biotech Ltd. positions itself as a developer of novel immunomodulatory agents that aim to improve efficacy while reducing toxicity. The company faces competition from large multinational pharmaceutical firms and other biotechnology companies pursuing similar checkpoint inhibitor T cell engager and small molecule approaches. Its competitive advantages include the masked tri specific design of CAPTN three specific that confines immune activation to the tumor microenvironment the broad tissue coverage of CEACAM1 targeting by CM24 and the dual inhibition of IRS1 2 and STAT3 by NT219.

The company’s ultimate customers are patients with cancer who receive treatment through hospitals oncology clinics and healthcare providers. Purple Biotech Ltd. also anticipates forming partnerships with pharmaceutical companies that could assist in clinical development manufacturing and commercialization of its candidates.